Capecitabine-Induced Coronary Vasospasm
Capecitabine, an oral prodrug of 5-fluorouracil (5-FU), is approved for early-stage and advanced colorectal cancer and metastatic breast cancer. Cardiotoxicity of 5-FU is well described in the literature. However, cardiac adverse effects of capecitabine are poorly described. We report a case of coro...
Main Authors: | Danish Henry, Francine Rudzik, Allison Butts, Aju Mathew |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2016-10-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/450544 |
Similar Items
-
Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study
by: Jianjun Peng, et al.
Published: (2018-05-01) -
Capecitabine-induced severe diabetes and hypokalemia: a case report
by: Qiaoling Yang, et al.
Published: (2022-04-01) -
Capecitabine-induced-coronary-vasospasm leading to polymorphic ventricular tachycardia and cardiac arrest
by: Maciej Kabat, et al.
Published: (2024-02-01) -
Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy
by: Uğur Nadir Karakulak, et al.
Published: (2016-02-01) -
Capecitabine-induced activation of actinic keratosis: A common but underrecognized adverse event
by: Samantha Marley, et al.
Published: (2021-03-01)